Late-line treatment in metastatic gastric cancer: today and tomorrow.

ABSTRACT: Survival for patients with unresectable advanced or recurrent gastric cancer (GC) remains poor and the historical lack of evidence-based therapeutic options after second-line therapy is reflected in current clinical guidelines for this condition. Despite uncertainty about optimal therapeutic strategies, further treatment is appropriate for some patients after failure of second line and may prolong survival. This approach has been reported in clinical trials and is becoming more common in real-world clinical settings. Several prognostic factors may increase the likelihood that a patient will be eligible for treatment in the third-line setting, including geographic location, status at diagnosis and response to treatment. There has been little progress over the last decade until the results f

SUBMITTER: Smyth EC 

PROVIDER: S-EPMC6713955 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature